SL
CRL icon

Salomon & Ludwin’s Charles River Laboratories CRL Stock Holding History

Salomon & Ludwin’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Hold
61
– – ﹤0.01% 1412
2026
Q1 		$10.6K Hold
61
– – ﹤0.01% 1495
2025
Q4 		$12.7K Hold
61
– – ﹤0.01% 1275
2025
Q3 		$10.8K Buy
+61
New +$9.69K ﹤0.01% 1247

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Salomon & Ludwin's CRL Position: Q2 2026 in Review

Salomon & Ludwin held its Charles River Laboratories (CRL) position steady in Q2 2026 at 61 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Salomon & Ludwin first reported a position in CRL in Q3 2025 and has held it in 4 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Salomon & Ludwin held 61 shares of Charles River Laboratories worth $14K as of Q2 2026.
  • Salomon & Ludwin left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1412 holding.
  • Salomon & Ludwin first reported a position in Charles River Laboratories in Q3 2025 and has held it in 4 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.